Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice | springermedicine.com

Springer Medicine

Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2014 | Research

Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice

Authors: Yunxia Zhang, Jing Wang, Mulan Ren, Miao Li, Dengyu Chen, Junsong Chen, Fangfang Shi, Xiaoying Wang, Jun Dou

Published in: Journal of Ovarian Research | Issue 1/2014

Login to get access

Abstract

Background

The human umbilical cord mesenchymal stem cells (hUCMSCs) have the ability to migrate into tumors and therefore have been considered as an alternative source of mesenchymal progenitors for the therapy of malignant diseases. The present study was aimed to investigate effect of hUCMSCs as vehicles for a constant source of transgenic interleukin-21 (IL-21) on ovarian cancer in vivo.

Methods

The hUCMSCs were engineered to express IL-21 via lentiviral vector- designated ‘hUCMSCs-LV-IL-21’, and then were transplanted into SKOV3 ovarian cancer xenograft-bearing nude mice. The therapeutic efficacy and mechanisms of this procedure on ovarian cancer was evaluated.

Results

The isolated hUCMSCs were induced to differentiate efficiently into osteoblast and adipocyte lineages in vitro. The expressed IL-21 in the supernatant from hUCMSCs-LV-IL-21 obviously stimulated splenocyte’s proliferation. The hUCMSCs-LV-IL-21 significantly reduced SKOV3 ovarian cancer burden in mice indicated by tumor sizes compared with control mice. The expressed IL-21 not only regulated the levels of IFN-γ and TNF-α in the mouse serum but also increased the expression of NKG2D and MIC A molecules in the tumor tissues. The down regulation of β-catenin and cyclin-D1 in the tumor tissues may refer to the inhibition of SKOV3 ovarian cancer growth in mice. In addition, hUCMSCs did not form gross or histological teratomas up to 60 days posttransplantation in murine lung, liver, stomach and spleen.

Conclusion

These results clearly indicate a safety and usability of hUCMSCs-LV- IL-21 in ovarian cancer gene therapy, suggesting the strategy may be a promising new method for clinical treatment of ovarian cancer.

Available only for authorised users

1.

Friedenstein AJ: Osteogenetic activity of transplanted transitional epithelium. Acta Anat (Basel) 1961, 45: 31–59. 10.1159/000141739CrossRef

2.

Kern S, Eichler H, Stoeve J, Klüter H, Bieback K: Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24: 1294–1301. 10.1634/stemcells.2005-0342CrossRefPubMed

3.

Castillo-Melendez M, Yawno T, Jenkin G, Miller SL: Stem cell therapy to protect and repair the developing brain: a review of mechanisms of action of cord blood and amnion epithelial derived cells. Front Neurosci 2013, 2,7: 194.

4.

Romanov YA, Svintsitskaya VA, Smirnov VN: Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSClike cells from umbilical cord. Stem Cells 2003, 21: 105–110. 10.1634/stemcells.21-1-105CrossRefPubMed

5.

Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp DO, Tukun A, Uckan D, Can A: Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells 2007, 25: 319–331. 10.1634/stemcells.2006-0286CrossRefPubMed

6.

Troyer DL, Weiss ML: Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells 2008, 26: 591–599. 10.1634/stemcells.2007-0439PubMedCentralCrossRefPubMed

7.

Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH: Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004, 103: 1669–1675. 10.1182/blood-2003-05-1670CrossRefPubMed

8.

Rachakatla RS, Marini F, Weiss ML, Tamura1 M, Troyer1 D: Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther 2007, 14: 828–835. 10.1038/sj.cgt.7701077CrossRefPubMed

9.

Ghaedi M, Soleimani M, Taghvaie NM: Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. J Gene Med 2011, 13: 171–180. 10.1002/jgm.1552CrossRefPubMed

10.

Lee DH, Ahn Y, Kim SU: Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 2009, 15: 4925–4934. 10.1158/1078-0432.CCR-08-3076CrossRefPubMed

11.

Hakkarainen T, Hemminki A, Pereboev AV, Barker SD, Asiedu CK, Strong TV, Kanerva A, Wahlfors J, Curiel DT: CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. Clin Cancer Res 2003, 9: 619–624.PubMed

12.

Kristiansen G, Denkert C, Schlns K, Dahl E, Pilarsky C, Hauptmann S: CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002, 161: 1215–1221. 10.1016/S0002-9440(10)64398-2PubMedCentralCrossRefPubMed

13.

Quiros RM, Valianou M, Godwin AK, Cukierman E: Ovarian normal and tumor associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix- dependent manner. Gynecol Oncol 2008, 110: 99–109. 10.1016/j.ygyno.2008.03.006PubMedCentralCrossRefPubMed

14.

Dou J, Chen G, Wang J, Zhao F, Chen J, He XF, Tang Q, Chu L: Preliminary study on mouse interleukin 21 application in tumor gene therapy. Cell Mol Immunol 2004, 1: 388–396.

15.

Dou J, Chu L, Zhao F, Tang Q, Zhang A, Zhang L, Wang Y, Li Y, Cao M, Gu N: Study of immunotherapy of murine myeloma by an IL-21-based tumor vaccine in BALB/C mice. Cancer Biol Ther 2007, 6: 1871–1879. 10.4161/cbt.6.12.4960CrossRefPubMed

16.

Kim SS, Kim HS, Fan Q, Kim DW, Kaufman HL: Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther 2009, 17: 380–388. 10.1038/mt.2008.249PubMedCentralCrossRefPubMed

17.

Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT: Immune responses in the draining lymphnodes against cancer: Implications for immunotherapy. Cancer Metastasis Rev 2006, 25: 233–242. 10.1007/s10555-006-8503-7CrossRefPubMed

18.

Steiner D, Gelovani J, Savoldo B, Robinson SN, Decker WK, Brouard N, Najjar A, Xing D, Yang H, Li S, Marini F, Zweidler McKay PA, Bollard CM, Shpall EJ, Dotti G, Simmons P: Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells. Stem Cells 2009, 27: 1932–1940. 10.1002/stem.111PubMedCentralCrossRefPubMed

19.

Dou J, Wang Y, Wang J, Zhao F, Li Y, Cao WH, Hu K, He XF, Chu L, Jiang C, Gu N: Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model. Immunobiology 2009, 214: 483–492. 10.1016/j.imbio.2008.11.002CrossRefPubMed

20.

Weihua H, Jing W, Jun D, Xiangfeng H, Fengshu Z, Cuilian J: Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Cell Transplant 2011, 20: 669–680. 10.3727/096368910X536509CrossRef

21.

Wang HS, Hung SC, Peng ST: Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells 2004, 22: 1330. 10.1634/stemcells.2004-0013CrossRefPubMed

22.

Bailey MM, Wang L, Bode CJ, Mitchell KE, Detamore MS: A comparison of human umbilical cord matrix stem cells and temporomandibular joint condylar chondrocytes for tissue engineering temporomandibular joint condylar cartilage. Tissue Eng 2003, 2007: 13.

23.

Ryu CH, Park SH, Park SA, Kim SM, Lim JY, Jeong CH: Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum Gene Ther 2011, 22: 733–743. 10.1089/hum.2010.187CrossRefPubMed

24.

Bieback K, Kern S, Kluter H, Eichler H: Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004, 22: 625–634. 10.1634/stemcells.22-4-625CrossRefPubMed

25.

Pittenger MF, Mackay AM, Beck CB, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284: 143–147. 10.1126/science.284.5411.143CrossRefPubMed

26.

Bingbing W, Ninghan F, Feng Z, Chun L, Jiantang S, Lixin H: Construction and identification of recombinant lentiviral vector containing HIV-1 Tat gene and its expression in 293T cells. J Biomed Res 2010, 24: 58–63. 10.1016/S1674-8301(10)60009-7CrossRef

27.

Mateos J, De la Fuente A, Lesende-Rodriguez I, Fernández-Pernas P, Arufe MC, Blanco FJ: Lamin A deregulation in human mesenchymal stem cells promotes an impairment in their chondrogenic potential and imbalance in their response to oxidative stress. Stem Cell Res 2013, 11: 1137–1148. 10.1016/j.scr.2013.07.004CrossRefPubMed

28.

Lecoeur H, Février M, Garcia S, Riviére Y, Gougeon ML: A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. Immunol Methods 2001, 253: 177–187. 10.1016/S0022-1759(01)00359-3CrossRef

29.

Banerjee S, Nandyala A, Podili R, Katoch VM, Murthy KJ, Hasnain SE: Mycobacterium tuberculosis (Mtb) isocitrate dehydrogenases show strong B cell response and distinguish vaccinated with controls from TB patients. Proc Natl Acad Sci 2004, 101: 12652–12657. 10.1073/pnas.0404347101PubMedCentralCrossRefPubMed

30.

Perez SA, Mahaira LG, Sotiropoulou PA, Grit zapis AD, Iliopoulou EG, Niarchos DK, Cacoullos NT, Kavalakis YG, Antsaklis AI, Sotiriadou NN, Baxevanis CN, Papamichil M: Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol 2006, 18: 49–58.CrossRefPubMed

31.

Chen D, Zhang Y, Wang J, Chen J, Yang C, Cai K, Wang X, Shi F, Dou J: MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117 + CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. Ovarian Res 2013, 6: 50. 10.1186/1757-2215-6-50CrossRef

32.

Dou J, Liu P, Wang J, Zhang X: Effect of hepatitis C virus core shadow protein expressed in human hepatoma cell line on human gene expression profiles. Gastroenterol Hepatol 2006, 21: 1794–1800. 10.1111/j.1440-1746.2006.04380.xCrossRef

33.

Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G: CD133 antigen expression in ovarian cancer. BMC Cancer 2009, 9: 221. 10.1186/1471-2407-9-221PubMedCentralCrossRefPubMed

34.

Liu J, Han G, Liu H, Qin C: Suppression of Cholangiocarcinoma Cell Growth by Human Umbilical Cord Mesenchymal Stem Cells: A Possible Role of Wnt and Akt Signaling. PLoS One 2013, 30: e62844.CrossRef

35.

Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004, 96: 1593–1603. 10.1093/jnci/djh299CrossRefPubMed

36.

Yang F, Zeng Q, Yu G, Li S, Wang CY: Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal 2006, 18: 679–687. 10.1016/j.cellsig.2005.06.015CrossRefPubMed

37.

Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SPS: Aberrant Wnt/b-catenin signaling in pancreatic adenocarcinoma. Neoplasia 2006, 8: 279–289. 10.1593/neo.05607PubMedCentralCrossRefPubMed

Title: Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice
Authors: Yunxia Zhang
Jing Wang
Mulan Ren
Miao Li
Dengyu Chen
Junsong Chen
Fangfang Shi
Xiaoying Wang
Jun Dou
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2014
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-7-8

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties